Patents by Inventor Mark L. Peterson
Mark L. Peterson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8088733Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective agonists of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Such compounds are useful as medicaments for treatment and prevention of a range of medical conditions characterized by disturbed gastrointestinal motility including, but not limited to, post-surgical gastroparesis and post-operative ileus in combination with opioid-induced bowel dysfunction. These agents are effective for multiple disorders at dose levels equivalent to those required to treat a single disorder.Type: GrantFiled: July 6, 2007Date of Patent: January 3, 2012Assignee: Tranzyme Pharma Inc.Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
-
Publication number: 20110288163Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: ApplicationFiled: June 30, 2011Publication date: November 24, 2011Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
-
Publication number: 20110245459Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.Type: ApplicationFiled: February 28, 2011Publication date: October 6, 2011Inventors: Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
-
Publication number: 20110237785Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.Type: ApplicationFiled: February 28, 2011Publication date: September 29, 2011Inventors: Éric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
-
Patent number: 8022252Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.Type: GrantFiled: August 25, 2008Date of Patent: September 20, 2011Assignee: Tranzyme Pharma Inc.Inventors: Pierre Deslongchamps, Yves Dory, Kamel Benakli, Éric Marsault, Luc Ouellet, Mahesh Ramaseshan, Martin Vezina, Daniel Fortin, Ruoxi Lan, Shigui Li, Gérald Villeneuve, Hamid R. Hoveyda, Sylvie Beaubien, Mark L. Peterson
-
Publication number: 20090312540Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target, in particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.Type: ApplicationFiled: May 26, 2009Publication date: December 17, 2009Inventors: Pierre Deslongchamps, Yves Dory, Luc Ouellet, Gerald Villeneuve, Mahesh Ramaseshan, Daniel Fortin, Mark L. Peterson, Hamid R. Hoveyda, Sylvie Beaubien, Eric Marsault, Graeme L. Fraser
-
Publication number: 20090240027Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6, n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.Type: ApplicationFiled: November 19, 2008Publication date: September 24, 2009Inventors: Eric Marsault, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Sylvie Beaubien, Luc Ouellet, Carl St-Louis, Sophie Beauchemin
-
Publication number: 20090198050Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: ApplicationFiled: October 31, 2008Publication date: August 6, 2009Inventors: Eric Marsault, Luc Ouellet, Carl St-Louis, Sylvie Beaubien, Kamel Benakli, Hamid R. Hoveyda, Mark L. Peterson, Shridhar Bhat
-
Publication number: 20090170757Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: ApplicationFiled: December 11, 2008Publication date: July 2, 2009Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
-
Patent number: 7550431Abstract: Novel spatially-defined macrocyclic compounds incorporating peptide bond surrogates are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.Type: GrantFiled: August 2, 2004Date of Patent: June 23, 2009Assignee: Tranzyme Pharma Inc.Inventors: Pierre Deslongchamps, Yves Dory, Luc Ouellet, Gérald Villeneuve, Mahesh Ramaseshan, Daniel Fortin, Mark L. Peterson, Hamid R. Hoveyda, Sylvie Beaubien, Éric Marsault, Graeme L. Fraser
-
Publication number: 20090137817Abstract: Novel spatially-defined macrocyclic compounds containing specific conformational control elements are disclosed. Libraries of these macrocycles are then used to select one or more macrocycle species that exhibit a specific interaction with a particular biological target. In particular, compounds according to the invention are disclosed as agonists or antagonists of a mammalian motilin receptor and a mammalian ghrelin receptor.Type: ApplicationFiled: August 25, 2008Publication date: May 28, 2009Inventors: Pierre Deslongchamps, Yves Dory, Kamel Benakli, Eric Marsault, Luc Ouellet, Mahesh Ramaseshan, Martin Vezina, Daniel Fortin, Ruoxi Lan, Shigui Li, Gerald Villeneuve, Hamid R. Hoveyda, Sylvie Beaubien, Mark L. Peterson
-
Patent number: 7491695Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: June 10, 2005Date of Patent: February 17, 2009Assignee: Tranzyme Pharma Inc.Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
-
Patent number: 7476653Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: June 10, 2005Date of Patent: January 13, 2009Assignee: Tranzyme Pharma, Inc.Inventors: Hamid R. Hoveyda, Mark L. Peterson, Graeme L. Fraser, Mahesh Ramaseshan
-
Publication number: 20080194672Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: ApplicationFiled: February 8, 2008Publication date: August 14, 2008Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, David Drutz, Eric Marsault, Luc Ouellet, Mark L. Peterson, Zhigang Wang
-
Publication number: 20040137886Abstract: A system for distributing electronic coupons includes plural wireless mobile terminals, such as cellular phones or personal digital assistants (PDAs), a customer profile database, and a server capable of accessing the customer profile database and communicating with the wireless mobile terminals over a wireless network. The database stores customer profiles for each of the wireless mobile terminals. The profiles include customer data, such as customer preferences and the current location of each wireless terminal. The server selectively transfers one or more electronic coupons to at least one of the wireless mobile terminals based on a comparison between the customer profiles and seller filtering criteria. A seller interface permits sellers to enter the seller filtering criteria. The filtering criteria can include the physical location of the seller so that coupons are sent only to those wireless terminals at or near the seller's location.Type: ApplicationFiled: November 21, 2003Publication date: July 15, 2004Inventors: Monte Ross, Mark L. Peterson, Matthew H. Klapman
-
Patent number: 5943653Abstract: A system for providing data related to discounted services available near a given location. The system includes a memory storing compressed service data representative of a plurality of services in various locations categorized by type of service and compressed coupon data representative of discounts available for the services. The system also includes a book of coupons corresponding to the discounted services wherein the coupon data includes identifying numbers which identify locations of coupons within the coupon book corresponding to the discounts available for the services. A data entry circuit receives and compresses input data identifying a desired category of services and the given location and a microprocessor, receiving and responsive to the compressed input data, selectively retrieves the service data and coupon data from the memory.Type: GrantFiled: March 7, 1996Date of Patent: August 24, 1999Assignee: Ultradata Systems, Inc.Inventors: Monte Ross, Mark L. Peterson, Leonard R. Missler
-
Patent number: 5241069Abstract: This invention relates to the new process for preparing the 1R-cis isomer of carbovir, (1R-cis)-amino-1,9-dihydro-9-[4-(hydroxymethyl)-2-cyclopenten-1-yl]-6H-pur in-6-one, an antiviral agent and intermediates of the formula (Vlb) use in that process ##STR1## wherein X is chloro, bromo or iodo and R is (C.sub.1-6) alkyl.Type: GrantFiled: November 6, 1991Date of Patent: August 31, 1993Assignees: Glaxo Inc., Univeristy of MinnesootaInventors: Robert Vince, Mark L. Peterson, John W. Lackey, Robert A. Mook, Jr., John J. Partridge
-
Patent number: 5229947Abstract: A data processing device for providing data related to the categories of services available at locations along a highway in response to operator input is disclosed. The device includes a memory, a keyboard for entering input data identifying a desired service and an origin position into the memory. The input data is compressed before it is stored in the memory. The memory stores predetermined data in a compressed form related to the categories of services available at locations along the highway. The device also includes a microprocessor for retrieving from the memory the predetermined data which is a function of the input data. The microprocessor expands the retrieved compressed data into an operator readable form and provides the expanded data to a display for displaying the expanded retrieved data such as restaurants, gas stations, motels, or other services along the highway.Type: GrantFiled: March 28, 1991Date of Patent: July 20, 1993Assignee: Laser Data Technology, Inc.Inventors: Monte Ross, Mark L. Peterson, Leonard R. Missler
-
Patent number: RE42013Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: December 11, 2009Date of Patent: December 28, 2010Assignee: Tranzyme Pharma Inc.Inventors: Hamid Hoveyda, Mark L. Peterson, Graeme L. Fraser, Mahesh Ramaseshan
-
Patent number: RE42624Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: December 11, 2009Date of Patent: August 16, 2011Assignee: Tranzyme Pharma Inc.Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson